Last updated on August 2020

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor


Brief description of study

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Clinical Study Identifier: NCT04145349

Find a site near you

Start Over

Mayo Clinic-Jacksonville

Jacksonville, FL United States
  Connect »

UCL- Saint Luc

Bruxelles, Belgium
  Connect »

Centre Leon Berard

Lyon Cedex 08, France
  Connect »

Institut Curie

Paris CEDEX 05, France
  Connect »

Royal Marsden Hospital

Sutton, United Kingdom
  Connect »

Childrens Hospital of Alabama

Birmingham, AL United States
  Connect »

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Childrens Hospital of Los Angeles

Los Angeles, CA United States
  Connect »

University of Minnesota Hospital

Minneapolis, MN United States
  Connect »

Riley Hospital for Children

Indianapolis, IN United States
  Connect »

Nationwide Children's Hosp

Columbus, OH United States
  Connect »

Cook Children's Hospital

Fort Worth, TX United States
  Connect »

Texas Childrens Hospital

Houston, TX United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.